Georg Mann

AIEOP‐BFM Consensus Guidelines 2016 for Flow Cytometric Immunophenotyping of Pediatric Acute Lymphoblastic Leukemia

Barbara Buldini, Giuseppe Basso, Richard Ratei, 2018, Cytometry. Part B, Clinical cytometry.

Long-term outcome in children with relapsed ALL by risk-stratified salvage therapy: results of trial acute lymphoblastic leukemia-relapse study of the Berlin-Frankfurt-Münster Group 87.

Ulrich Göbel, M. Schrappe, H. G. Einsiedel, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95.

Christian Urban, Martin Zimmermann, Martin Stanulla, 2007, Blood.

Prognostic significance and modalities of flow cytometric minimal residual disease detection in childhood acute lymphoblastic leukemia.

Michael N Dworzak, Ulrike Pötschger, D. Printz, 2002, Blood.

Use of allogeneic hematopoietic stem-cell transplantation based on minimal residual disease response improves outcomes for children with relapsed acute lymphoblastic leukemia in the intermediate-risk group.

Arndt Borkhardt, Christina Peters, A. Borkhardt, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.